SOURCE: Celtaxsys Inc.

Celtaxsys Inc.

December 01, 2015 08:03 ET

Celtaxsys to Present at 27th Annual Piper Jaffray Healthcare Conference

ATLANTA, GA--(Marketwired - December 01, 2015) - Celtaxsys, a clinical stage drug development company focused on advancing foundational medicine for patients suffering from orphan inflammatory diseases, will be presenting at the 27th Annual Piper Jaffray Healthcare Conference in New York.

Date: Wednesday, December 2, 2015

1:50 pm Eastern Time

The New York Palace Hotel, 4th Floor, Kennedy 2 (Track Seven)

The company is currently enrolling a landmark Phase 2 lung function preservation trial in adult cystic fibrosis (CF) patients for its flagship compound, once daily oral acebilustat. The study, named EMPIRE CF (Evaluating Modulation of the Pulmonary Inflammatory Response in CF), is being conducted at approximately 60 clinical sites in the US and EU.

For more information about the ongoing CF trial, please visit

Acebilustat's ability to modulate excessive neutrophil-driven inflammation may be useful in the treatment of other orphan inflammatory diseases, such as hidradenitis suppurativa (HS) and pulmonary arterial hypertension (PAH). A Phase 2 proof of concept clinical trial of acebilustat in moderately severe acne vulgaris patients is underway to test the anti-inflammatory effects of once daily oral acebilustat in skin.

For more information about the ongoing acne vulgaris study, please visit

Contact Information